Acupuncture for Peripheral Neuropathy Induced by A/EC-T Chemotherapy in Early-Stage and Mid-Term Breast Cancer: A Randomized, Controlled, Trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900021665

Enrollment

Unknown

Registered

2019-03-04

Start date

2019-03-01

Completion date

Unknown

Last updated

2019-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy Induced Peripheral Neuropathy

Interventions

Group 1:Acupuncture/Normal acupucnture

Group 2:Shllow/Sham acupucnture

Group 3:no intervention

Eligibility

Sex/Gender

Female

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) over (including) 18 years old, less than (including) 70 years old; (2) according to the clinical/pathological staging was diagnosed as stage I-III breast cancer; (3) previously accepted A/EC-T 8 cycle chemotherapy, and the end of chemotherapy for more than 3 months; (4) sign the informed consent; (5) extremities numbness, tingling, leg warmers kind feeling changes of peripheral nerve symptoms, such as neural symptom and NCI CTCAE - level above II level; (6) KPS>70, ECOG physical state 0-2; (7) if medication is used to control neurological symptoms, it should be taken continuously for more than three months before the start of treatment, and the medication regimen remains unchanged during the treatment.

Exclusion criteria

Exclusion criteria: Any of the following will not be included in this study: (1) diabetic peripheral neuropathy or other peripheral neuropathy; (2) inflammatory, metabolic or neuropathic joint disease; (3) currently taking narcotic drugs; (4) serious complications; (5) severe coagulation dysfunction; (6) skin diseases in the acupuncture area; (7) the researcher considers it inappropriate to participate in the study; (8) received acupuncture treatment for peripheral neuropathy within the first 3 months of the study; (9) a history of cardiovascular, liver, respiratory, renal, blood, endocrine or neuropsychiatric diseases with clinical symptoms; (10) with mental, psychological, immune system diseases, severe digestive system diseases and other complications affecting treatment and efficacy evaluation; (11) patients with distant metastatic breast cancer.

Design outcomes

Primary

Measure	Time frame
NCI-CTCAE-Neurologic Symptom Rating;	—

Secondary

Measure	Time frame
Neuropathic-Pain Scale;electromyography;	—

Countries

China

Contacts

Public ContactLu Jing

First Affiliated Hospital of Nanjing Medical University, Jiangsu Privnce Hospital

lujing0728@163.com+86 15062216761

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026